The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

REDWOOD CITY, CA, USA & SHENZHEN, China I4, 2025 I LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S.

Corticosteroids inhibit antigen presentation, cytokine production, and proliferation of lymphocytes. Corticosteroids have a profound effect on the concentration of peripheral blood leukocytes.

Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent T reg –microglia crosstalk Nasal anti ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

CD79b is a unique tumor antigen receptor that is highly expressed ... leading to enhanced phagocytosis and depletion of cancer cells. The initial study of LTZ-301 will be conducted in patients ...